News

Dupixent eases flares, aids lung function with COPD: NOTUS trial

Dupixent (dupilumab) as an add-on maintenance treatment significantly eased exacerbations and lung symptom severity while improving lung function and quality of life — among people with moderate to severe chronic obstructive pulmonary disease (COPD). That’s according to published data from the Phase 3 NOTUS clinical trial (NCT04456673), which…

Tezepelumab may reduce COPD exacerbations, trial data suggests

Tezepelumab, which is approved for severe asthma, tended to reduce the frequency of exacerbations in adults with moderate to very severe chronic obstructive pulmonary disease (COPD). That’s according data from the international, proof-of-concept Phase 2a COURSE clinical trial (NCT04039113) that included 337 COPD patients irrespective of emphysema, chronic…

Plant-based diet may halve emphysema risk for young smokers

Young adults who smoke or have smoked may halve their risk of developing emphysema — a form of chronic obstructive pulmonary disease (COPD) — by eating a nutritionally rich, plant-based diet, a new U.S. study suggests. The study, “A Plant-Centered Diet is Inversely Associated With Radiographic Emphysema: Findings…

FDA seeks more data on Dupixent COPD clinical trials

The U.S. Food and Drug Administration (FDA) has asked for more data from clinical trials that tested Dupixent (dupilumab) in people with chronic obstructive pulmonary disease (COPD), Regeneron Pharmaceuticals, one of the therapy’s developers, announced during a company webcast. The requested data pertains to subgroup analyses from two…

ALA awareness campaign highlights jobs that pose risk of COPD

A new campaign will highlight the ways certain jobs, including those related to mining, agriculture, and manufacturing, can increase the risk of developing chronic obstructive pulmonary disease (COPD). Long-term exposure to dust, chemicals, fumes, and vapors in the workplace may all lead to COPD, said the American Lung…

Working on the night shift tied to higher risk of COPD in study

Permanent night shift work is associated with a nearly 50% higher risk of developing chronic obstructive pulmonary disease (COPD) relative to day work, according to a large study of U.K. data. The risk of COPD was even higher among permanent night shift workers with high genetic susceptibility to the…

Dosing begins in clinical trial of potential COPD therapy APG808

Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial of APG808, the company’s anti-inflammatory injection therapy for chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory disorders. “Launching our second clinical program, ahead of initial timeline expectations, brings us one step closer to providing…